The latest interim report explicitly describes CRO collaborations with innovative pharmaceutical companies and new contracts, separately disclosing research services/CRO. Clinical specialty testing remains the main business; included as diversified with group-level financials.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Public financial snapshot
Amounts retain their original currency and units. Consolidated group revenue is not standalone CRO/CDMO service revenue. Year-to-date periods are not standalone quarters.
Period
Currency / basis
Revenue
Net profit
Operating cash flow
Report
FY2025 2025-12-31
CNY IFRS / consolidated
933,565,000
-58,742,000 Loss attributable to owners of the parent
Consolidated group totals include diagnostic, research and other products/services; they are not CRO or central laboratory segment revenue.
The report uses CNY thousands, converted here to CNY. Parent-attributable loss was CNY 58.742 million; total group loss of CNY 55.149 million is not a substitute.
The source reports a 7.61% increase in parent-attributable loss. Net income YoY is left blank to avoid treating a change in loss as conventional earnings growth.
Comparable adjusted group net income attributable to owners of the parent is not disclosed. Only adjusted segment pretax results are available and are not treated as the PRC measure excluding nonrecurring items.
The research services and CRO segment generated CNY 59.570 million in 2025, approximately 6.4% of group revenue; not all of this was commercial drug R&D.
2026H1 · Reporting notes
Consolidated group totals include diagnostic, research and other products/services; they are not CRO or central laboratory segment revenue.
The report uses CNY thousands. Parent-attributable loss was CNY 18.864 million and total group loss was CNY 18.057 million; these are kept separate.
The source reports a 47.7% narrowing of parent-attributable loss; this is not converted into conventional earnings growth.
Adjusted segment pretax results are not adjusted group net income attributable to owners of the parent; adjustedProfit is left blank.
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
The 2026H1 report discloses approximately RMB 7.2 million in new CRO contracts. Research services/CRO revenue was RMB 30.823 million, including research services rather than pure CRO.
HKEX:09960; the 2025 annual report and latest 2026 report were read from original consolidated statements.
Bio-S Pharmaceutical reported that its joint platform with XtalPi, Hangzhou Baijingyao Biotechnology, was unveiled in Shanghai on November 5. The partners described plans to combine AI-driven discovery with experimental validation, drug development, and clinical translation. The November 6 announcement presents an operating strategy and platform milestone, rather than a quantified licensing transaction or validated clinical outcome.
Fresenius signed an exclusive development agreement with WuXi Biologics providing access to up to 37 biosimilar candidates over the next decade. Initial work is expected to focus on polatuzumab vedotin and teprotumumab biosimilars. Fresenius retains selection flexibility and commercialization economics; the candidate count is an option-based opportunity, not 37 approved products.
Biocytogen reported consolidated revenue of RMB1.403 billion, up 49.09%, and attributable net income of RMB312.4 million for the nine months ended September 30, 2026. Attributable net income increased 173.77%. The group combines animal models, research services, and antibody licensing activities. The quarterly filing is unaudited and covers the year-to-date period.
Combined research services/CRO revenue is not pure CRO. Stand-alone CRO operating cash flow and net profit attributable to shareholders are not disclosed.
No comparable group adjusted net profit attributable to shareholders was found; it is not estimated from segment adjusted pre-tax results.
E4 denotes evidence of services/platforms, not a service-quality rating or a drug candidate’s clinical stage.
